Evidence map›Paper›PMID 36406181›Full record

ReviewOncology letters2022

Cancer stem cells markers in ovarian cancer: Clinical and therapeutic significance (Review).

Patrycja Królewska-Daszczyńska, Dominika Wendlocha, Marta Smycz-Kubańska, Sebastian Stępień, Aleksandra Mielczarek-Palacz

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncology letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Patrycja Królewska-DaszczyńskaDepartment of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec Medical University of Silesia, 40-055 Katowice, Poland.
Dominika WendlochaDepartment of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec Medical University of Silesia, 40-055 Katowice, Poland.
Marta Smycz-KubańskaDepartment of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec Medical University of Silesia, 40-055 Katowice, Poland.
Sebastian StępieńDepartment of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec Medical University of Silesia, 40-055 Katowice, Poland.
Aleksandra Mielczarek-PalaczDepartment of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec Medical University of Silesia, 40-055 Katowice, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is a gynecological neoplasm that can be found in women, which, due to diagnostic difficulties, is often detected at advanced stages when treatment becomes a significant problem. Moreover, in a number of cases there is a cancer recurrence and resistance to standard chemotherapy treatment. It has been suggested that cancer stem cells (CSCs) that were not eradicated during therapy may be responsible for this. For this reason, effective therapeutic methods eliminating CSCs are being studied, such as therapy targeting CSCs markers. In addition, numerous studies have also drawn attention to the usefulness of CSCs markers in predicting disease progression and assessing patient's prognosis as well as their importance in the development of treatment resistance. The present review presented research on selected CSCs markers, which may be of significant prognostic and therapeutic importance in ovarian cancer.

Indexed as

cancer stem cellsmarkersovarian cancer

Identifiers

PMID36406181
PMCPMC9667454

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.